Abstract CT214: CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC
Year: 2020
Type: conference-abstract
Source: Cancer Research
Authors: Bruce E. Johnson, Tae Min Kim, T. Jeroen N. Hiltermann, Fabrice Barlesi, Christian Grohe, Yasushi Goto, Orvar Gunnarsson, Tobias Overbeck, Noemi Reguart, Martin Wermke, Gilberto Castro Castro, Enriqueta Felip, Alastair Greystoke, Benjamin J. Solomon, Stephanie Deudon, Anne-Laure Louveau, Vanessa Passos, Daniel SW Tan
Institutions: Dana-Farber Cancer Institute, Seoul National University Hospital, University Medical Center Groningen, Aix-Marseille Université, Evangelische Lungenklinik Berlin, National Cancer Centre Japan, National University Hospital of Iceland, Universitätsmedizin Göttingen, University of Göttingen, Hospital Clínic de Barcelona, Instituto do Câncer do Estado de São Paulo, Vall d'Hebron Institute of Oncology, Newcastle upon Tyne Hospital, Peter MacCallum Cancer Centre, Novartis (Switzerland), Novartis (France), National Cancer Centre Singapore
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3083312408